bluebird bio (NASDAQ:BLUE) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note released on Friday. The firm issued a sell rating on the biotechnology company’s stock.

A number of other analysts have also weighed in on BLUE. Barclays increased their price objective on shares of bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 31st. JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Wells Fargo & Company dropped their price objective on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. Finally, Baird R W lowered bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $51.00.

bluebird bio Trading Up 7.7 %

BLUE stock opened at $4.08 on Friday. bluebird bio has a twelve month low of $3.56 and a twelve month high of $28.60. The stock has a market capitalization of $39.67 million, a price-to-earnings ratio of -0.11 and a beta of 0.76. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The firm’s fifty day simple moving average is $5.53 and its two-hundred day simple moving average is $7.73.

Institutional Investors Weigh In On bluebird bio

A number of institutional investors and hedge funds have recently bought and sold shares of BLUE. Geode Capital Management LLC grew its position in shares of bluebird bio by 3.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after buying an additional 166,771 shares in the last quarter. State Street Corp lifted its stake in bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after acquiring an additional 43,382 shares during the period. FMR LLC grew its holdings in bluebird bio by 8.1% during the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after acquiring an additional 186,903 shares in the last quarter. BNP Paribas Financial Markets increased its position in bluebird bio by 2,270.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 355,562 shares during the period. Finally, Barclays PLC raised its holdings in shares of bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 184,605 shares in the last quarter. 87.43% of the stock is owned by institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.